Generation Bio Co.
Generation Bio Co. GBIO Peers
See (GBIO) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GBIO | $4.27 | +1.43% | 286.2M | -3.95 | -$1.08 | N/A |
| VRTX | $470.13 | +2.54% | 120.7B | -123.39 | -$3.81 | N/A |
| REGN | $560.93 | +2.82% | 59.6B | 14.25 | $39.36 | +0.32% |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $325.28 | +1.49% | 42.4B | -154.93 | -$2.10 | N/A |
| ARGX | $571.23 | +0.90% | 34.9B | 34.84 | $16.38 | N/A |
| BNTX | $111.44 | +2.32% | 26.8B | -29.64 | -$3.76 | N/A |
| RPRX | $36.10 | +1.26% | 20.3B | 14.73 | $2.45 | +2.39% |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| SMMT | $26.54 | +0.76% | 19.7B | -78.06 | -$0.34 | N/A |
Stock Comparison
GBIO vs VRTX Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, VRTX has a market cap of 120.7B. Regarding current trading prices, GBIO is priced at $4.27, while VRTX trades at $470.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas VRTX's P/E ratio is -123.39. In terms of profitability, GBIO's ROE is -0.76%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, GBIO is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs REGN Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, REGN has a market cap of 59.6B. Regarding current trading prices, GBIO is priced at $4.27, while REGN trades at $560.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas REGN's P/E ratio is 14.25. In terms of profitability, GBIO's ROE is -0.76%, compared to REGN's ROE of +0.15%. Regarding short-term risk, GBIO is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs SGEN Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, GBIO is priced at $4.27, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas SGEN's P/E ratio is -57.19. In terms of profitability, GBIO's ROE is -0.76%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, GBIO is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs ALNY Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, ALNY has a market cap of 42.4B. Regarding current trading prices, GBIO is priced at $4.27, while ALNY trades at $325.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas ALNY's P/E ratio is -154.93. In terms of profitability, GBIO's ROE is -0.76%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, GBIO is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs ARGX Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, ARGX has a market cap of 34.9B. Regarding current trading prices, GBIO is priced at $4.27, while ARGX trades at $571.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas ARGX's P/E ratio is 34.84. In terms of profitability, GBIO's ROE is -0.76%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, GBIO is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs BNTX Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, BNTX has a market cap of 26.8B. Regarding current trading prices, GBIO is priced at $4.27, while BNTX trades at $111.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas BNTX's P/E ratio is -29.64. In terms of profitability, GBIO's ROE is -0.76%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, GBIO is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs RPRX Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, RPRX has a market cap of 20.3B. Regarding current trading prices, GBIO is priced at $4.27, while RPRX trades at $36.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas RPRX's P/E ratio is 14.73. In terms of profitability, GBIO's ROE is -0.76%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, GBIO is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs BGNE Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, GBIO is priced at $4.27, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas BGNE's P/E ratio is -22.55. In terms of profitability, GBIO's ROE is -0.76%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, GBIO is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs SMMT Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, SMMT has a market cap of 19.7B. Regarding current trading prices, GBIO is priced at $4.27, while SMMT trades at $26.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas SMMT's P/E ratio is -78.06. In terms of profitability, GBIO's ROE is -0.76%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, GBIO is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs DNA-WT Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, GBIO is priced at $4.27, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, GBIO's ROE is -0.76%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, GBIO is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs UTHR Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, UTHR has a market cap of 13.4B. Regarding current trading prices, GBIO is priced at $4.27, while UTHR trades at $297.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas UTHR's P/E ratio is 11.87. In terms of profitability, GBIO's ROE is -0.76%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, GBIO is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs GMAB Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, GMAB has a market cap of 13.4B. Regarding current trading prices, GBIO is priced at $4.27, while GMAB trades at $21.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas GMAB's P/E ratio is 12.82. In terms of profitability, GBIO's ROE is -0.76%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, GBIO is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs INCY Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, INCY has a market cap of 13.3B. Regarding current trading prices, GBIO is priced at $4.27, while INCY trades at $68.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas INCY's P/E ratio is 344.50. In terms of profitability, GBIO's ROE is -0.76%, compared to INCY's ROE of +0.01%. Regarding short-term risk, GBIO is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs MRNA Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, MRNA has a market cap of 12.7B. Regarding current trading prices, GBIO is priced at $4.27, while MRNA trades at $32.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas MRNA's P/E ratio is -3.75. In terms of profitability, GBIO's ROE is -0.76%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, GBIO is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs KRTX Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, GBIO is priced at $4.27, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas KRTX's P/E ratio is -28.09. In terms of profitability, GBIO's ROE is -0.76%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, GBIO is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs EXEL Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, EXEL has a market cap of 12.1B. Regarding current trading prices, GBIO is priced at $4.27, while EXEL trades at $44.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas EXEL's P/E ratio is 20.31. In terms of profitability, GBIO's ROE is -0.76%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, GBIO is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs BMRN Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, BMRN has a market cap of 11.4B. Regarding current trading prices, GBIO is priced at $4.27, while BMRN trades at $59.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas BMRN's P/E ratio is 21.93. In terms of profitability, GBIO's ROE is -0.76%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, GBIO is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs ASND Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, ASND has a market cap of 10B. Regarding current trading prices, GBIO is priced at $4.27, while ASND trades at $165.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas ASND's P/E ratio is -24.20. In terms of profitability, GBIO's ROE is -0.76%, compared to ASND's ROE of +1.91%. Regarding short-term risk, GBIO is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs RXDX Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, GBIO is priced at $4.27, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas RXDX's P/E ratio is -56.47. In terms of profitability, GBIO's ROE is -0.76%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, GBIO is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs VRNA Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, VRNA has a market cap of 8.9B. Regarding current trading prices, GBIO is priced at $4.27, while VRNA trades at $105.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas VRNA's P/E ratio is -52.50. In terms of profitability, GBIO's ROE is -0.76%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, GBIO is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs IMGN Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, GBIO is priced at $4.27, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas IMGN's P/E ratio is -111.55. In terms of profitability, GBIO's ROE is -0.76%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, GBIO is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs BBIO Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, BBIO has a market cap of 8.7B. Regarding current trading prices, GBIO is priced at $4.27, while BBIO trades at $45.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas BBIO's P/E ratio is -12.86. In terms of profitability, GBIO's ROE is -0.76%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, GBIO is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs BPMC Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, GBIO is priced at $4.27, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas BPMC's P/E ratio is -51.58. In terms of profitability, GBIO's ROE is -0.76%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, GBIO is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs TECH Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, TECH has a market cap of 8.3B. Regarding current trading prices, GBIO is priced at $4.27, while TECH trades at $53.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas TECH's P/E ratio is 64.00. In terms of profitability, GBIO's ROE is -0.76%, compared to TECH's ROE of +0.06%. Regarding short-term risk, GBIO is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs CERE Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, GBIO is priced at $4.27, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas CERE's P/E ratio is -16.47. In terms of profitability, GBIO's ROE is -0.76%, compared to CERE's ROE of -0.43%. Regarding short-term risk, GBIO is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs ROIVW Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, GBIO is priced at $4.27, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, GBIO's ROE is -0.76%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, GBIO is more volatile compared to ROIVW. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs ROIV Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, ROIV has a market cap of 7.8B. Regarding current trading prices, GBIO is priced at $4.27, while ROIV trades at $11.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas ROIV's P/E ratio is -15.33. In terms of profitability, GBIO's ROE is -0.76%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, GBIO is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs CORT Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, CORT has a market cap of 7.3B. Regarding current trading prices, GBIO is priced at $4.27, while CORT trades at $69.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas CORT's P/E ratio is 60.07. In terms of profitability, GBIO's ROE is -0.76%, compared to CORT's ROE of +0.20%. Regarding short-term risk, GBIO is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs RVMD Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, RVMD has a market cap of 7.1B. Regarding current trading prices, GBIO is priced at $4.27, while RVMD trades at $38.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas RVMD's P/E ratio is -9.54. In terms of profitability, GBIO's ROE is -0.76%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, GBIO is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs HALO Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, HALO has a market cap of 7.1B. Regarding current trading prices, GBIO is priced at $4.27, while HALO trades at $57.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas HALO's P/E ratio is 15.30. In terms of profitability, GBIO's ROE is -0.76%, compared to HALO's ROE of +1.22%. Regarding short-term risk, GBIO is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs JAZZ Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, JAZZ has a market cap of 7B. Regarding current trading prices, GBIO is priced at $4.27, while JAZZ trades at $116.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas JAZZ's P/E ratio is 15.81. In terms of profitability, GBIO's ROE is -0.76%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, GBIO is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs MDGL Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, MDGL has a market cap of 7B. Regarding current trading prices, GBIO is priced at $4.27, while MDGL trades at $313.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas MDGL's P/E ratio is -16.38. In terms of profitability, GBIO's ROE is -0.76%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, GBIO is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs IONS Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, IONS has a market cap of 6.7B. Regarding current trading prices, GBIO is priced at $4.27, while IONS trades at $41.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas IONS's P/E ratio is -14.03. In terms of profitability, GBIO's ROE is -0.76%, compared to IONS's ROE of -0.92%. Regarding short-term risk, GBIO is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs RETA Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, GBIO is priced at $4.27, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas RETA's P/E ratio is -66.29. In terms of profitability, GBIO's ROE is -0.76%, compared to RETA's ROE of +0.47%. Regarding short-term risk, GBIO is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs AMRN Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, AMRN has a market cap of 6.3B. Regarding current trading prices, GBIO is priced at $4.27, while AMRN trades at $15.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas AMRN's P/E ratio is -3.49. In terms of profitability, GBIO's ROE is -0.76%, compared to AMRN's ROE of -0.17%. Regarding short-term risk, GBIO is more volatile compared to AMRN. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs TGTX Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, TGTX has a market cap of 5.9B. Regarding current trading prices, GBIO is priced at $4.27, while TGTX trades at $37.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas TGTX's P/E ratio is 149.48. In terms of profitability, GBIO's ROE is -0.76%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, GBIO is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs NUVL Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, NUVL has a market cap of 5.8B. Regarding current trading prices, GBIO is priced at $4.27, while NUVL trades at $80.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas NUVL's P/E ratio is -18.25. In terms of profitability, GBIO's ROE is -0.76%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, GBIO is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs RYTM Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, RYTM has a market cap of 5.8B. Regarding current trading prices, GBIO is priced at $4.27, while RYTM trades at $87.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas RYTM's P/E ratio is -31.36. In terms of profitability, GBIO's ROE is -0.76%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, GBIO is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs CRSP Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, CRSP has a market cap of 5.7B. Regarding current trading prices, GBIO is priced at $4.27, while CRSP trades at $65.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas CRSP's P/E ratio is -14.69. In terms of profitability, GBIO's ROE is -0.76%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, GBIO is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs ABCM Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, GBIO is priced at $4.27, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, GBIO's ROE is -0.76%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, GBIO is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs ISEE Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, GBIO is priced at $4.27, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas ISEE's P/E ratio is -22.44. In terms of profitability, GBIO's ROE is -0.76%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, GBIO is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs TLX Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, TLX has a market cap of 5.5B. Regarding current trading prices, GBIO is priced at $4.27, while TLX trades at $16.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas TLX's P/E ratio is 180.89. In terms of profitability, GBIO's ROE is -0.76%, compared to TLX's ROE of +0.14%. Regarding short-term risk, GBIO is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs AXSM Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, AXSM has a market cap of 5B. Regarding current trading prices, GBIO is priced at $4.27, while AXSM trades at $102.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas AXSM's P/E ratio is -17.77. In terms of profitability, GBIO's ROE is -0.76%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, GBIO is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs MRUS Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, MRUS has a market cap of 4.7B. Regarding current trading prices, GBIO is priced at $4.27, while MRUS trades at $63.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas MRUS's P/E ratio is -15.21. In terms of profitability, GBIO's ROE is -0.76%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, GBIO is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs PCVX Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, PCVX has a market cap of 4.6B. Regarding current trading prices, GBIO is priced at $4.27, while PCVX trades at $35.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas PCVX's P/E ratio is -8.95. In terms of profitability, GBIO's ROE is -0.76%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, GBIO is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs SLNO Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, SLNO has a market cap of 4.5B. Regarding current trading prices, GBIO is priced at $4.27, while SLNO trades at $86.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas SLNO's P/E ratio is -18.15. In terms of profitability, GBIO's ROE is -0.76%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, GBIO is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs CYTK Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, CYTK has a market cap of 4.5B. Regarding current trading prices, GBIO is priced at $4.27, while CYTK trades at $37.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas CYTK's P/E ratio is -7.12. In terms of profitability, GBIO's ROE is -0.76%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, GBIO is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs ALPN Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, GBIO is priced at $4.27, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas ALPN's P/E ratio is -101.52. In terms of profitability, GBIO's ROE is -0.76%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, GBIO is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs ALKS Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, ALKS has a market cap of 4.5B. Regarding current trading prices, GBIO is priced at $4.27, while ALKS trades at $27.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas ALKS's P/E ratio is 12.86. In terms of profitability, GBIO's ROE is -0.76%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, GBIO is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs KRYS Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, KRYS has a market cap of 4.4B. Regarding current trading prices, GBIO is priced at $4.27, while KRYS trades at $151.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas KRYS's P/E ratio is 36.43. In terms of profitability, GBIO's ROE is -0.76%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, GBIO is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs OPT Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, GBIO is priced at $4.27, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas OPT's P/E ratio is -1.52. In terms of profitability, GBIO's ROE is -0.76%, compared to OPT's ROE of +2.60%. Regarding short-term risk, GBIO is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs MTSR Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, MTSR has a market cap of 4.1B. Regarding current trading prices, GBIO is priced at $4.27, while MTSR trades at $39.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas MTSR's P/E ratio is -15.53. In terms of profitability, GBIO's ROE is -0.76%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, GBIO is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs AKRO Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, AKRO has a market cap of 4.1B. Regarding current trading prices, GBIO is priced at $4.27, while AKRO trades at $51.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas AKRO's P/E ratio is -13.81. In terms of profitability, GBIO's ROE is -0.76%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, GBIO is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs MRTX Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, GBIO is priced at $4.27, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas MRTX's P/E ratio is -4.82. In terms of profitability, GBIO's ROE is -0.76%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, GBIO is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs ZLAB Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, ZLAB has a market cap of 4.1B. Regarding current trading prices, GBIO is priced at $4.27, while ZLAB trades at $37.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas ZLAB's P/E ratio is -14.80. In terms of profitability, GBIO's ROE is -0.76%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, GBIO is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs ADMA Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, ADMA has a market cap of 4.1B. Regarding current trading prices, GBIO is priced at $4.27, while ADMA trades at $17.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas ADMA's P/E ratio is 20.30. In terms of profitability, GBIO's ROE is -0.76%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, GBIO is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs LEGN Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, LEGN has a market cap of 4.1B. Regarding current trading prices, GBIO is priced at $4.27, while LEGN trades at $44.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas LEGN's P/E ratio is -37.31. In terms of profitability, GBIO's ROE is -0.76%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, GBIO is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs RNA Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, RNA has a market cap of 4B. Regarding current trading prices, GBIO is priced at $4.27, while RNA trades at $33.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas RNA's P/E ratio is -11.18. In terms of profitability, GBIO's ROE is -0.76%, compared to RNA's ROE of -0.27%. Regarding short-term risk, GBIO is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs SRRK Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, SRRK has a market cap of 3.8B. Regarding current trading prices, GBIO is priced at $4.27, while SRRK trades at $39.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas SRRK's P/E ratio is -15.56. In terms of profitability, GBIO's ROE is -0.76%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, GBIO is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs ACAD Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, GBIO is priced at $4.27, while ACAD trades at $22.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas ACAD's P/E ratio is 16.48. In terms of profitability, GBIO's ROE is -0.76%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, GBIO is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs ACLX Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, ACLX has a market cap of 3.8B. Regarding current trading prices, GBIO is priced at $4.27, while ACLX trades at $68.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas ACLX's P/E ratio is -22.82. In terms of profitability, GBIO's ROE is -0.76%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, GBIO is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs RYZB Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, GBIO is priced at $4.27, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas RYZB's P/E ratio is -57.86. In terms of profitability, GBIO's ROE is -0.76%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, GBIO is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs CBAY Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, GBIO is priced at $4.27, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas CBAY's P/E ratio is -32.81. In terms of profitability, GBIO's ROE is -0.76%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, GBIO is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs PTCT Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, PTCT has a market cap of 3.7B. Regarding current trading prices, GBIO is priced at $4.27, while PTCT trades at $46.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas PTCT's P/E ratio is 7.13. In terms of profitability, GBIO's ROE is -0.76%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, GBIO is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs VKTX Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, VKTX has a market cap of 3.6B. Regarding current trading prices, GBIO is priced at $4.27, while VKTX trades at $32.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas VKTX's P/E ratio is -27.67. In terms of profitability, GBIO's ROE is -0.76%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, GBIO is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs SWTX Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, GBIO is priced at $4.27, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas SWTX's P/E ratio is -13.78. In terms of profitability, GBIO's ROE is -0.76%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, GBIO is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs AAPG Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, AAPG has a market cap of 3.4B. Regarding current trading prices, GBIO is priced at $4.27, while AAPG trades at $39.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas AAPG's P/E ratio is -52.65. In terms of profitability, GBIO's ROE is -0.76%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, GBIO is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs PTGX Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, PTGX has a market cap of 3.4B. Regarding current trading prices, GBIO is priced at $4.27, while PTGX trades at $54.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas PTGX's P/E ratio is 70.50. In terms of profitability, GBIO's ROE is -0.76%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, GBIO is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs MLTX Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, MLTX has a market cap of 3.4B. Regarding current trading prices, GBIO is priced at $4.27, while MLTX trades at $53.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas MLTX's P/E ratio is -23.29. In terms of profitability, GBIO's ROE is -0.76%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, GBIO is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs KYMR Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, KYMR has a market cap of 3.2B. Regarding current trading prices, GBIO is priced at $4.27, while KYMR trades at $45.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas KYMR's P/E ratio is -14.71. In terms of profitability, GBIO's ROE is -0.76%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, GBIO is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs IMVT Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, IMVT has a market cap of 3.1B. Regarding current trading prices, GBIO is priced at $4.27, while IMVT trades at $17.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas IMVT's P/E ratio is -6.57. In terms of profitability, GBIO's ROE is -0.76%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, GBIO is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs MORF Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, GBIO is priced at $4.27, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas MORF's P/E ratio is -14.88. In terms of profitability, GBIO's ROE is -0.76%, compared to MORF's ROE of -0.22%. Regarding short-term risk, GBIO is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs MOR Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, GBIO is priced at $4.27, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas MOR's P/E ratio is -12.64. In terms of profitability, GBIO's ROE is -0.76%, compared to MOR's ROE of -1.84%. Regarding short-term risk, GBIO is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs CRNX Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, CRNX has a market cap of 2.9B. Regarding current trading prices, GBIO is priced at $4.27, while CRNX trades at $30.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas CRNX's P/E ratio is -8.02. In terms of profitability, GBIO's ROE is -0.76%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, GBIO is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs RXRX Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, RXRX has a market cap of 2.8B. Regarding current trading prices, GBIO is priced at $4.27, while RXRX trades at $6.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas RXRX's P/E ratio is -3.63. In terms of profitability, GBIO's ROE is -0.76%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, GBIO is more volatile compared to RXRX. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs KDNY Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, GBIO is priced at $4.27, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas KDNY's P/E ratio is -12.47. In terms of profitability, GBIO's ROE is -0.76%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, GBIO is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs IMRA Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, IMRA has a market cap of 2.6B. Regarding current trading prices, GBIO is priced at $4.27, while IMRA trades at $52.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas IMRA's P/E ratio is N/A. In terms of profitability, GBIO's ROE is -0.76%, compared to IMRA's ROE of -0.41%. Regarding short-term risk, GBIO is more volatile compared to IMRA. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs MYOV Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, GBIO is priced at $4.27, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas MYOV's P/E ratio is -14.05. In terms of profitability, GBIO's ROE is -0.76%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, GBIO is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs MIRM Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, MIRM has a market cap of 2.6B. Regarding current trading prices, GBIO is priced at $4.27, while MIRM trades at $52.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas MIRM's P/E ratio is -32.42. In terms of profitability, GBIO's ROE is -0.76%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, GBIO is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs NAMS Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, NAMS has a market cap of 2.6B. Regarding current trading prices, GBIO is priced at $4.27, while NAMS trades at $22.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas NAMS's P/E ratio is -12.48. In terms of profitability, GBIO's ROE is -0.76%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, GBIO is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs LGND Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, LGND has a market cap of 2.6B. Regarding current trading prices, GBIO is priced at $4.27, while LGND trades at $132.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas LGND's P/E ratio is -18.17. In terms of profitability, GBIO's ROE is -0.76%, compared to LGND's ROE of -0.16%. Regarding short-term risk, GBIO is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs CPRX Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, CPRX has a market cap of 2.5B. Regarding current trading prices, GBIO is priced at $4.27, while CPRX trades at $20.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas CPRX's P/E ratio is 13.31. In terms of profitability, GBIO's ROE is -0.76%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, GBIO is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs NAMSW Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, NAMSW has a market cap of 2.5B. Regarding current trading prices, GBIO is priced at $4.27, while NAMSW trades at $11.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas NAMSW's P/E ratio is N/A. In terms of profitability, GBIO's ROE is -0.76%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, GBIO is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for GBIO.
GBIO vs RARE Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, RARE has a market cap of 2.5B. Regarding current trading prices, GBIO is priced at $4.27, while RARE trades at $26.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas RARE's P/E ratio is -4.54. In terms of profitability, GBIO's ROE is -0.76%, compared to RARE's ROE of -1.86%. Regarding short-term risk, GBIO is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs APLS Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, APLS has a market cap of 2.5B. Regarding current trading prices, GBIO is priced at $4.27, while APLS trades at $19.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas APLS's P/E ratio is -11.04. In terms of profitability, GBIO's ROE is -0.76%, compared to APLS's ROE of -1.00%. Regarding short-term risk, GBIO is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs XENE Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, XENE has a market cap of 2.4B. Regarding current trading prices, GBIO is priced at $4.27, while XENE trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas XENE's P/E ratio is -9.73. In terms of profitability, GBIO's ROE is -0.76%, compared to XENE's ROE of -0.32%. Regarding short-term risk, GBIO is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs IBRX Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, IBRX has a market cap of 2.4B. Regarding current trading prices, GBIO is priced at $4.27, while IBRX trades at $2.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas IBRX's P/E ratio is -4.75. In terms of profitability, GBIO's ROE is -0.76%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, GBIO is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs PRVB Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, GBIO is priced at $4.27, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas PRVB's P/E ratio is -16.43. In terms of profitability, GBIO's ROE is -0.76%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, GBIO is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs APGE Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, APGE has a market cap of 2.4B. Regarding current trading prices, GBIO is priced at $4.27, while APGE trades at $39.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas APGE's P/E ratio is -10.97. In terms of profitability, GBIO's ROE is -0.76%, compared to APGE's ROE of -0.19%. Regarding short-term risk, GBIO is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs LBPH Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, GBIO is priced at $4.27, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas LBPH's P/E ratio is -26.66. In terms of profitability, GBIO's ROE is -0.76%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, GBIO is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs AGIO Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, AGIO has a market cap of 2.3B. Regarding current trading prices, GBIO is priced at $4.27, while AGIO trades at $39.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas AGIO's P/E ratio is 3.44. In terms of profitability, GBIO's ROE is -0.76%, compared to AGIO's ROE of +0.50%. Regarding short-term risk, GBIO is more volatile compared to AGIO. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs DICE Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, GBIO is priced at $4.27, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas DICE's P/E ratio is -21.91. In terms of profitability, GBIO's ROE is -0.76%, compared to DICE's ROE of +0.56%. Regarding short-term risk, GBIO is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs BEAM Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, BEAM has a market cap of 2.2B. Regarding current trading prices, GBIO is priced at $4.27, while BEAM trades at $21.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas BEAM's P/E ratio is -4.67. In terms of profitability, GBIO's ROE is -0.76%, compared to BEAM's ROE of -0.44%. Regarding short-term risk, GBIO is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs GLPG Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, GLPG has a market cap of 2.2B. Regarding current trading prices, GBIO is priced at $4.27, while GLPG trades at $32.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas GLPG's P/E ratio is -10.31. In terms of profitability, GBIO's ROE is -0.76%, compared to GLPG's ROE of -0.06%. Regarding short-term risk, GBIO is more volatile compared to GLPG. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs CNTA Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, CNTA has a market cap of 2.2B. Regarding current trading prices, GBIO is priced at $4.27, while CNTA trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas CNTA's P/E ratio is -8.60. In terms of profitability, GBIO's ROE is -0.76%, compared to CNTA's ROE of -0.57%. Regarding short-term risk, GBIO is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs CALT Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, GBIO is priced at $4.27, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas CALT's P/E ratio is -22.73. In terms of profitability, GBIO's ROE is -0.76%, compared to CALT's ROE of -1.67%. Regarding short-term risk, GBIO is more volatile compared to CALT. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs HRMY Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, HRMY has a market cap of 2.1B. Regarding current trading prices, GBIO is priced at $4.27, while HRMY trades at $36.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas HRMY's P/E ratio is 14.00. In terms of profitability, GBIO's ROE is -0.76%, compared to HRMY's ROE of +0.24%. Regarding short-term risk, GBIO is more volatile compared to HRMY. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs IRON Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, IRON has a market cap of 2.1B. Regarding current trading prices, GBIO is priced at $4.27, while IRON trades at $60.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas IRON's P/E ratio is -15.61. In terms of profitability, GBIO's ROE is -0.76%, compared to IRON's ROE of -0.23%. Regarding short-term risk, GBIO is more volatile compared to IRON. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.
GBIO vs ARWR Comparison
GBIO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GBIO stands at 286.2M. In comparison, ARWR has a market cap of 2.1B. Regarding current trading prices, GBIO is priced at $4.27, while ARWR trades at $14.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GBIO currently has a P/E ratio of -3.95, whereas ARWR's P/E ratio is -12.06. In terms of profitability, GBIO's ROE is -0.76%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, GBIO is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for GBIO.